Skip to Content

Notice

  • PDF
  • Document Details
  • Table of Contents
  • Related Documents
  • Public Comments
  • Regulations.gov Data
  • Sharing
  • Print
  • Document Statistics
  • Other Formats
  • Public Inspection
Published Document: 2022-27836 (87 FR 78638)

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

On August 19, 2022, Piramal Pharma Solutions submitted a notification of proposed production activity to the FTZ ( printed page 78639) Board for its facility within FTZ 35, in Sellersville, Pennsylvania.

The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the Federal Register inviting public comment (87 FR 52505-52506, August 26, 2022). On December 19, 2022, the applicant was notified of the FTZ Board's decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board's regulations, including Section 400.14.

Dated: December 19, 2022.

Andrew McGilvray,

Executive Secretary.

[FR Doc. 2022-27836 Filed 12-21-22; 8:45 am]

BILLING CODE 3510-DS-P